Quest Diagnostics announces availability of the AD-Detect on questhealth

Quest Diagnostics announced the availability of the AD-Detect Test for Alzheimer’s Disease on questhealth.com – the first blood test available for consumer purchase that helps assess potential risk of developing Alzheimer’s disease based on a brain protein that contributes to the condition. AD-Detect is a screening test that uses plasma, the liquid component of blood, from a single blood draw to evaluate levels of amyloid beta proteins to help detect early signs associated with the risk of developing Alzheimer’s disease. Amyloid beta proteins are known to accumulate and form plaques in the brain, which are linked to the progression of Alzheimer’s disease. AD-Detect evaluates the ratio of two peptides of amyloid beta, Abeta42 and Abeta40, in plasma. The new test from Quest may be appropriate for individuals who believe they are experiencing cognitive decline or if an individual’s loved one recognizes potential signs of mild cognitive impairment, such as memory loss, as well as those with family history of Alzheimer’s disease – even if they are not exhibiting symptoms, are 65 years of age or older, or have had brain trauma or head injury.